Skip to main content
$0.200 0.005 (2.56%)

High

$0.21

Low

$0.19

Trades

113

Turnover

$359,726

Volume

1,808,064
30 June 2023 at 4:10pm
If you were already registered, log in here.

Short Interest

ASIC data, 1 Oct 2025

% Shorted

0.00% 0.02
vs 0.03% prior report

Most Shorted Rank

548th
of 717 shorted ASX stocks

Peak Short

1.12%
May 2020

Days to Cover

0.1
at 50d avg vol
Subject
IXC Ann: Half Yearly Report and Accounts

IXC Ann: Upcoming Presentations at 48th Annual NANOS Meeting

IXC Ann: New Executive Director and Chairman Agreements

IXC Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IXC Ann: Notice of Investor Call and Appendix 4C

IXC Ann: Change of Registry Address

IXC Ann: UK R&D Tax Rebate

IXC Ann: Appointment IIH EVOLVE Phase III Trial Steering Group Chair

IXC Ann: Results of Meeting

IXC Ann: Chairman's Address to Shareholders at AGM

IXC Ann: Withdrawal of AGM Resolutions

IXC Ann: Invex to Present at Bell Potter Healthcare Conference

IXC Ann: Notice of Webinar & Investor Presentation

IXC Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021

IXC Ann: Notice of Annual General Meeting/Proxy Form

IXC Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IXC Ann: Presentation at EANS 2021 Congress

IXC Ann: Date of AGM and Closing Date for Director Nominations

IXC Ann: Notice of Investor Call and Presentation

IXC Ann: Exclusive Collaboration and Manufacturing Agreement

IXC Ann: Trading Halt

IXC Ann: Corporate Governance Statement

IXC Ann: Appendix 4G

IXC Ann: Appendix 4E and Annual Report

IXC Ann: Invex Granted Key European Patent for Exenatide

IXC Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IXC Ann: Appendix 2A

IXC Ann: Notice of Upcoming Release of Securities from Escrow

IXC Ann: Investor Presentation

IXC Ann: Invex Receives Written Response from FDA on Type C Meeting

IXC Ann: Formulation and Manufacturing Update

IXC Ann: Invex Granted Type C Meeting with FDA

IXC Ann: Appendix 4C - quarterly

IXC Ann: Appendix 3G

IXC Ann: Change of Director's Interest Notice

IXC Ann: Results of Meeting

IXC Ann: Chairman's Address to Shareholders

IXC Ann: Invex Files Pre-IND/Type B Meeting Request with US FDA

IXC Ann: Investor Presentation

IXC Ann: Invex to Present at Upcoming Small Caps Conference

IXC Ann: Postcard to Shareholders

IXC Ann: Notice of General Meeting/Proxy Form

IXC Ann: US Trademark Granted for Presendin

IXC Ann: Initial Director's Interest Notice

IXC Ann: Invex Appoints Dr Megan Baldwin as Non-Executive Director

IXC Ann: Half Yearly Report and Accounts

IXC Ann: Appendix 4C - quarterly

IXC Ann: Invex Successfully Concludes Protocol Assistance with EMA

IXC Ann: Ceasing to be a substantial holder

IXC Ann: Invex to Present at Bell Potter Healthcare Conference

If you were already registered, log in here.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL
S88
MAV
CX8
MTX $12m raise
ATW $7.5m raise
RDO $30m raise
ABC $5m raise
RGS